menu
    • menu
    [{"orgOrder":0,"company":"Be Biopharma","sponsor":"Longwood Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Series A Financing","leadProduct":"Engineer B cells","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Be Biopharma","amount2":0.050000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Be Biopharma \/ Longwood Fund","highestDevelopmentStatusID":"1","companyTruncated":"Be Biopharma \/ Longwood Fund"},{"orgOrder":0,"company":"Be Biopharma","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Series B Financing","leadProduct":"Engineered B Cell Medicine","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Be Biopharma","amount2":0.13,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"","sponsorNew":"Be Biopharma \/ ARCH Venture Partners","highestDevelopmentStatusID":"1","companyTruncated":"Be Biopharma \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Be Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"BE-101","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Be Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Be Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Be Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Be Biopharma","sponsor":"MaxCyte","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"B Cell-based Therapy","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Be Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Be Biopharma \/ Be Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Be Biopharma \/ Be Biopharma"},{"orgOrder":0,"company":"Be Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Be Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Be Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Be Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Be Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"BE-101","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Be Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Be Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Be Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Be Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"BE-101","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Be Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Be Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Be Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Be Biopharma","sponsor":"Arch Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"BE-101","moa":"","graph1":null,"graph2":null,"graph3":"Be Biopharma","amount2":0.080000000000000002,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"Be Biopharma \/ Arch Venture Partners","highestDevelopmentStatusID":null,"companyTruncated":"Be Biopharma \/ Arch Venture Partners"},{"orgOrder":0,"company":"Be Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"B Cell-based Therapy","moa":"","graph1":null,"graph2":null,"graph3":"Be Biopharma","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"Be Biopharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Be Biopharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Be Biopharma

    Menu

    Be Biopharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Be Biopharma

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Be Biopharma

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BE-101

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Arch Venture Partners

                            Deal Size : $82.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Be Bio Announces $82 Million Financing and Transition to Clinical Stage Company

                            Details : The financing is intended to support Be Bio in advancing BE-101 through clinical proof of concept, which is currently being evaluated for the treatment of hemophilia B.

                            Brand Name : BE-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 22, 2024

                            Lead Product(s) : BE-101

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Arch Venture Partners

                            Deal Size : $82.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Be Biopharma

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Be Biopharma

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : B Cell-based Therapy

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Be Biopharma Shows Preclinical Efficacy of Engineered B Cell Medicine for Hypophosphatasia

                            Details : Be Biopharma's preclinical data showcases the transformative potential of BCMs in producing active alkaline phosphatase (ALP), positioning BCMs as a promising treatment for Hypophosphatasia.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            September 30, 2024

                            Lead Product(s) : B Cell-based Therapy

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Be Biopharma

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Be Biopharma

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BE-101

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Be Bio’s haemophilia B treatment gains FDA orphan drug status

                            Details : BE-101 is an autologous B cell-derived ex vivo gene edited cell therapy candidate, whih is being evaluated for the treatment of patients with haemophilia B.

                            Brand Name : BE-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            June 05, 2024

                            Lead Product(s) : BE-101

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Be Biopharma

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Be Biopharma

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BE-101

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Be Biopharma Announces FDA Clearance of IND Application for BE-101 in Hemophilia B

                            Details : BE-101 an autologous first-in-class B Cell Medicine that is engineered to insert the human FIX gene into primary human B cells, allowing for expression of active FIX for the treatment of hemophilia B.

                            Brand Name : BE-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            May 28, 2024

                            Lead Product(s) : BE-101

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Be Biopharma

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Be Biopharma

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Be Biopharma Reveals New Preclinical Data for B Cell Medicine Targeting Hypophosphatasia

                            Details : A therapy combining CRISPR/Cas9 and AI-guided protein design modifies primary human B cells to produce ALP, an enzyme deficient in Hypophosphatasia patients.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            May 10, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Be Biopharma

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Be Biopharma

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : B Cell-based Therapy

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Recipient : MaxCyte

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            MaxCyte Signs License with Be Biopharma for Engineered B Cell Medicines

                            Details : Be Bio gains non-exclusive research, clinical, and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT platform to support the development of its BCMs programs.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 02, 2024

                            Lead Product(s) : B Cell-based Therapy

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Recipient : MaxCyte

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Be Biopharma

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Be Biopharma

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BE-101

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Be Bio Announces New Preclinical Data Demonstrating its Novel Engineered B Cell Medicine (BCM), BE-101, Produc...

                            Details : BE-101 is a novel engineered B cell medicine, which produces active and sustained levels of Factor IX (FIX) and it is currently being evaluated for the treatment of hemophilia B.​

                            Brand Name : BE-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            December 10, 2023

                            Lead Product(s) : BE-101

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Be Biopharma

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Be Biopharma

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Engineered B Cell Medicine

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : ARCH Venture Partners

                            Deal Size : $130.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Be Bio Closes $130 Million Financing to Pioneer Engineered B Cells, a New Class of Cellular Medicines

                            Details : Proceeds will advance autologous and allogeneic Engineered B Cell Medicine (BeCM) platforms, as well as progress pipeline candidates in oncology and rare disease toward investigational new drug (IND) applications.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 14, 2022

                            Lead Product(s) : Engineered B Cell Medicine

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : ARCH Venture Partners

                            Deal Size : $130.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Be Biopharma

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Be Biopharma

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Engineer B cells

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Longwood Fund

                            Deal Size : $52.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Be Biopharma Launches with $52 Million Series A Financing to Advance B Cells as Medicines

                            Details : The company plans to use this funding to precisely engineer B cells to treat a range of diseases, building on the pioneering work of Drs. Rawlings and James at Seattle Children’s Research Institute.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 22, 2020

                            Lead Product(s) : Engineer B cells

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Longwood Fund

                            Deal Size : $52.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth